Capital Fund Management S.A. Acquires 7,403 Shares of Bluebird Bio Inc. (BLUE)
Capital Fund Management S.A. increased its stake in Bluebird Bio Inc. (NASDAQ:BLUE) by 1,233.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 6,803 shares of the company’s stock after buying an additional 7,403 shares during the period. Capital Fund Management S.A.’s holdings in Bluebird Bio were worth $295,000 at the end of the most recent reporting period.
Several other large investors also recently modified their holdings of the company. Wellington Management Group LLP bought a new stake in shares of Bluebird Bio during the first quarter valued at about $51,095,000. State Street Corp increased its stake in shares of Bluebird Bio by 25.9% in the first quarter. State Street Corp now owns 1,201,936 shares of the company’s stock valued at $51,088,000 after buying an additional 247,254 shares in the last quarter. Franklin Resources Inc. increased its stake in shares of Bluebird Bio by 26.1% in the first quarter. Franklin Resources Inc. now owns 965,561 shares of the company’s stock valued at $41,036,000 after buying an additional 199,900 shares in the last quarter. TIAA CREF Investment Management LLC increased its stake in shares of Bluebird Bio by 134.0% in the first quarter. TIAA CREF Investment Management LLC now owns 339,424 shares of the company’s stock valued at $14,426,000 after buying an additional 194,367 shares in the last quarter. Finally, Tiverton Asset Management LLC bought a new stake in shares of Bluebird Bio during the first quarter valued at about $3,957,000.
Shares of Bluebird Bio Inc. (NASDAQ:BLUE) traded down 13.29% during mid-day trading on Friday, reaching $56.57. 4,144,106 shares of the company’s stock traded hands. The firm has a 50-day moving average of $63.71 and a 200 day moving average of $50.93. Bluebird Bio Inc. has a 12-month low of $35.37 and a 12-month high of $99.70. The company’s market cap is $2.10 billion.
Bluebird Bio (NASDAQ:BLUE) last issued its quarterly earnings data on Wednesday, August 3rd. The company reported ($1.59) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.44) by $0.15. Bluebird Bio had a negative net margin of 3,512.13% and a negative return on equity of 24.85%. The firm earned $1.55 million during the quarter, compared to analyst estimates of $2.01 million. During the same period in the previous year, the firm posted ($1.57) earnings per share. The company’s quarterly revenue was down 68.6% compared to the same quarter last year. Equities analysts forecast that Bluebird Bio Inc. will post ($6.19) EPS for the current year.
A number of research analysts recently weighed in on the stock. Goldman Sachs Group Inc. raised shares of Bluebird Bio from a “buy” rating to a “conviction-buy” rating and set a $135.00 target price for the company in a research report on Thursday, September 15th. Cantor Fitzgerald downgraded shares of Bluebird Bio from a “hold” rating to a “sell” rating and decreased their target price for the company from $65.24 to $37.00 in a research report on Friday. Leerink Swann raised their target price on shares of Bluebird Bio from $67.00 to $80.00 and gave the company an “outperform” rating in a research report on Friday. Maxim Group reaffirmed a “buy” rating and issued a $85.00 target price (down previously from $105.00) on shares of Bluebird Bio in a research report on Thursday, August 4th. Finally, Roth Capital assumed coverage on shares of Bluebird Bio in a research report on Thursday, September 22nd. They issued a “buy” rating and a $87.00 target price for the company. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and fourteen have assigned a buy rating to the company. Bluebird Bio has an average rating of “Buy” and a consensus target price of $91.60.
In other news, insider Eric Sullivan sold 416 shares of Bluebird Bio stock in a transaction on Monday, October 3rd. The stock was sold at an average price of $67.00, for a total value of $27,872.00. Following the completion of the sale, the insider now directly owns 5,891 shares of the company’s stock, valued at $394,697. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 3.50% of the stock is owned by insiders.
About Bluebird Bio
bluebird bio, Inc is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.
Want to see what other hedge funds are holding BLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bluebird Bio Inc. (NASDAQ:BLUE).
Receive News & Ratings for Bluebird Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluebird Bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.